The clinical benefit of the combination of VEGF and PD-1 inhibitors in HCC was confirmed by the Phase 3, randomized trial IMbrave150 comparing atezolizumab plus bevacizumab over sorafenib [155]. Here, VEGFA is linked to hepatocellular carcinoma.